|
Activity Number:
|
233
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Tuesday, August 5, 2008 : 8:30 AM to 10:20 AM
|
|
Sponsor:
|
Section on Health Policy Statistics
|
| Abstract - #300517 |
|
Title:
|
Using a Yardstick Approach To Enrich Understanding of Treatment Effect on Urge To Smoke: An Application to a Smoking Cessation Trial
|
|
Author(s):
|
Joseph C. Cappelleri*+ and Andrew G. Bushmakin and Riad Dirani
|
|
Companies:
|
Pfizer, Inc. and Pfizer, Inc. and Johnson & Johnson Pharmaceutical R&D, LLC
|
|
Address:
|
50 Pequot Avenue, New London, CT, 06320,
|
|
Keywords:
|
effect size ; clinical significance ; patient-reported outcome ; urge to smoke ; smoking cessation ; varenicline
|
|
Abstract:
|
We illustrate a way to enrich the interpretation of treatment effect on patient-reported outcomes. The study involved 1,025 smokers randomized to receive varenicline, bupropion, or placebo for 12 weeks. Urge to smoke, a patient-reported outcome, was measured by the Minnesota Nicotine Withdrawal Scale (MNWS). We divided the treatment effect size (difference between treatments on urge to smoke averaged over the first 7 weeks of treatment) by the criterion effect size (difference between non-smokers and smokers on urge to smoke at week 12 in the placebo group). Compared with placebo, varenicline reduced urge to smoke on MNWS that was about six-tenths of the way found between non-smokers and smokers. By benchmarking against two distinct clinical groups, the interpretation of treatment effect on patient-reported outcomes can be enriched.
|
- The address information is for the authors that have a + after their name.
- Authors who are presenting talks have a * after their name.
Back to the full JSM 2008 program |
